新型麦角灵类化合物作为5-羟色胺2A受体激动剂用于治疗情绪障碍
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
Abstract
Provided herein are novel ergolines as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders, and processes for preparing such compounds.
摘要
本文提供了作为5-HT2A激动剂的新型麦角灵、药物组合物、此类化合物在治疗情绪障碍中的用途以及制备此类化合物的方法。
相似文献
1
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
2
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
3
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
4
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
5
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.
ACS Med Chem Lett. 2025 May 9;16(6):933-934. doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.
6
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
7
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
8
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
9
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.
10
Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders.
ACS Med Chem Lett. 2025 Mar 13;16(4):508-509. doi: 10.1021/acsmedchemlett.5c00093. eCollection 2025 Apr 10.
本文引用的文献
1
5-HT receptors: Pharmacology and functional selectivity.
Pharmacol Rev. 2025 Jul;77(4):100059. doi: 10.1016/j.pharmr.2025.100059. Epub 2025 Apr 23.
2
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
3
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.
Brain Sci. 2025 Jan 25;15(2):117. doi: 10.3390/brainsci15020117.
4
Exploring DMT: Endogenous role and therapeutic potential.
Neuropharmacology. 2025 May 1;268:110314. doi: 10.1016/j.neuropharm.2025.110314. Epub 2025 Jan 18.
5
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
6
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
Zotero 插件